Form 4: Rallybio Director Liu Hui Granted Stock Options

Director Liu Hui of Rallybio Corp. was granted stock options for 28,500 shares on May 13, 2025, according to a Form 4 filing.

Summary

• A Form 4 filing reveals that Rallybio Corp. director Liu Hui was granted stock options on May 13, 2025.
• The options are for 28,500 shares of Rallybio's common stock.
• The exercise price of the options is $0.30 per share.
• The options vest on the earlier of May 13, 2026, or the date of the company's 2026 Annual Meeting of Stockholders.
• The options expire on May 13, 2035.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine grant of stock options, which is neither particularly positive nor negative on its own.

Positives

• The granting of stock options to a director aligns their interests with those of the shareholders, incentivizing them to work towards the company's success.

Industry Context

Stock option grants are a common practice in the biotechnology industry to incentivize and retain key personnel, aligning their interests with the long-term success of the company.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the biotech industry.
• Companies like Amgen, Biogen, and Gilead Sciences routinely grant stock options to their directors and officers as part of their overall compensation strategy.
• The size of the grant (28,500 shares) would need to be compared to similar grants at peer companies to determine if it is within industry norms.

Stakeholder Impact

• The stock option grant could have a slightly dilutive effect on existing shareholders if the options are exercised in the future.

Key Dates

Keywords

Form 4, Rallybio, Stock Options, Director, RLYB, Equity Incentive Plan